Skip to main content
Premium Trial:

Request an Annual Quote

CDx, Biomarker Company Flagship BioSciences Acquires IHCtec

NEW YORK (GenomeWeb News) – Companion diagnostics and biomarker development company Flagship Biosciences announced late on Monday its purchase of immunohistochemistry and immunofluorescence firm IHCtech for an undisclosed amount.

In a statement, Flagship President David Young said the deal provides his company "the opportunity to internally evaluate tissue staining and implement new processes that better equip immunohistochemistry operations for use in quantitative pathology with whole slide imaging analysis."

Patsy Ruegg, the owner and founder of IHCtech, added that the two companies have partnered on several new techniques and approaches for quantitation in immunohistochemistry, and Flagship's approaches to whole slide analysis and commitment to quantitative pathology "makes a perfect partner with IHCtech's expertise in high quality histology and immunohistochemistry."

Flagship, based in Flagstaff, Ariz., is focused on tissue-based companion diagnostics, immunohistochemistry biomarker development, and histopathology assessment of discovery, safety, and toxicity using brightfield and fluorescent whole slide imaging. IHCtech is headquartered at the Colorado Anschutz Medical Campus and provides histology, immunohistochemistry, and immunofluorescence services to the academic and pharmaceutical end markets.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.